12 min read

    Semaglutide Weight Loss Results: What to Really Expect in 2025

    Published:
    Last updated:
    Recently Updated
    Share:

    The Clinical Trial Data: What the Studies Show

    What did the STEP 1 trial measure?

    STEP 1 studied once-weekly injected semaglutide alongside lifestyle intervention in adults with overweight or obesity who did not have diabetes. Mean body-weight reduction in the semaglutide group was 14.9% at 68 weeks. This result describes the studied regimen and population.

    Source: Wilding et al., NEJM, 2021.

    Does that predict my results with Trimi?

    No. STEP 1 did not measure outcomes for Trimi or for Trimi's compounded preparations. A trial-group average does not predict an individual's result. Discuss treatment options, risks and expectations with a licensed provider. Compounded medications are not FDA-approved.

    Start Your Semaglutide Journey

    Get Started Today

    Related Articles

    Semaglutide

    Semaglutide Dosage Guide

    Detailed information on starting doses, titration schedules, and maintenance dosing for semaglutide.

    Read more
    Semaglutide

    Semaglutide Side Effects

    Understanding common and rare side effects of semaglutide and effective management strategies.

    Read more
    Semaglutide

    Semaglutide Clinical Results

    Analysis of STEP trial data and real-world clinical evidence for semaglutide efficacy.

    Read more

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    What weight-loss results can I expect on semaglutide?

    Semaglutide 2.4 mg/week (Wegovy) produces approximately 14.9% mean body-weight reduction at 68 weeks per the STEP 1 trial published in NEJM 2021 (vs 2.4% on placebo). Individual results vary; this is general information not medical advice.

    STEP 1 NEJM 2021: ~14.9% loss at 68 weeks.

    Key Takeaways

    • STEP 1 trial: semaglutide 2.4 mg/week + lifestyle produced ~14.9% mean body-weight reduction at 68 weeks vs 2.4% placebo (NEJM 2021).
    TET

    Written by Trimi Editorial Team

    Trimi publishes this educational content. This byline does not imply a clinical review.

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. Quotes and source attribution are preserved.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    (VialsRx is the former name of BelieveRx.)

    Really great customer service! Fast shipment.
    - Amy K.Facebook

    Editorial Standards

    Trimi publishes patient education with dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Novo Nordisk (2025). Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration.Read Study

    Was this article helpful?